作者
Jordan T Said, Mofei Liu, Jordan Talia, Sean B Singer, Yevgeniy R Semenov, Erin X Wei, Arash Mostaghimi, Caroline A Nelson, Anita Giobbie-Hurder, Nicole R LeBoeuf
发表日期
2022/5/1
期刊
JAMA dermatology
卷号
158
期号
5
页码范围
552-557
出版商
American Medical Association
简介
Importance
De novo bullous pemphigoid (BP) is a rare immune-mediated adverse event from immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of the anticancer therapy, but the risk factors for developing this toxic effect are unknown.
Objective
To compare potential risk factors for BP in patients treated with ICIs who did and did not develop BP.
Design, Setting, and Participants
This cohort and nested propensity score–matched case-control study was conducted at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Massachusetts General Hospital. All patients at these facilities with de novo BP after ICI treatment were compared with all patients on the cancer registry who were treated with ICIs between October 1, 2014, and December 31, 2020. Patients with incomplete or blinded data regarding the ICI agent or total cycles were excluded.
Exposures
In the cohort …
学术搜索中的文章
JT Said, M Liu, J Talia, SB Singer, YR Semenov… - JAMA dermatology, 2022